Sentinel surveillance for viral hepatitis C in China, 2016-2017.
10.3760/cma.j.issn.0254-6450.2019.01.009
- VernacularTitle:2016-2017年中国丙型肝炎哨点监测分析
- Author:
G W DING
1
;
S D YE
1
;
F X HEI
1
;
Q L LIAN
2
;
X D PEI
3
;
J Y BAI
4
;
D ZHOU
5
;
Q YANG
6
;
S HUI
7
;
W WANG
8
;
A X TU
9
;
L PANG
1
Author Information
1. Division of HCV and STD Prevention and Treatment, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
2. Department of High Risk Population Intervention, Institute of AIDS/STD Prevention and Treatment, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350001, China.
3. Surveillance Department, Institute of STD/AIDS Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610041, China.
4. Epidemiology Department, Division of AIDS/STD Control and Prevention, Tianjin Center for Disease Control and Prevention, Tianjin 300011, China.
5. Institute of AIDS/STD Control and Prevention, Liaoning Provincial Center for Disease Control and Prevention, Shenyang 110005, China.
6. Institute of AIDS/STD Control and Prevention, Jiangxi Provincial Center for Disease Control and Prevention, Nanchang 330029, China.
7. Institute of AIDS/STD Control and Prevention, Heilongjiang Provincial Center for Disease Control and Prevention, Harbin 150030, China.
8. Institute of AIDS/STD Prevention and Treatment, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang 050021, China.
9. Department of AIDS/STD Control and Prevention, Gansu Provincial Center for Disease Control and Prevention, Lanzhou 730030, China.
- Publication Type:Journal Article
- Keywords:
Antibody positive prevalence;
Hepatitis C virus;
Sentinel surveillance
- MeSH:
China/epidemiology*;
Cross-Sectional Studies;
Hepacivirus;
Hepatitis C/epidemiology*;
Hepatitis C Antibodies;
Humans;
Prevalence;
Sentinel Surveillance
- From:
Chinese Journal of Epidemiology
2019;40(1):41-45
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To understand the prevalence of hepatitis C virus (HCV) infection in 5 populations in China during 2016-2017 and provide evidence for the estimation of prevalence trend of hepatitis C and evaluation on the prevention and control effect. Methods: A total of 87 national sentinel surveillance sites for hepatitis C were set up in 31 provinces (autonomous regions and municipalities) of China to obtain the information about HCV infection prevalence in 5 populations, including volunteer blood donors, people receiving physical examination, patients receiving invasive diagnosis and treatment, patients receiving hemodialysis, and clients visiting family planning outpatient clinics. From April to June, 2016 and 2017, cross-sectional surveys were repeatedly conducted in the 5 populations and blood samples were collected from them for HCV antibody detection. Results: In 2016, 86 sentinel sites completed the surveillance (one sentinel site was not investigated), and 115 841 persons were surveyed. The overall HCV positive rate was 0.38% (442/115 841, 95%CI: 0.23%-0.53%). In 2017, all the 87 sentinel sites completed the surveillance, and 120 486 persons were surveyed. The overall HCV positive rate was 0.37% (449/120 486, 95%CI: 0.23%-0.52%). In 2016 and 2017, the anti-HCV positive rates were 4.46% (223/5 005, 95%CI: 2.18%-6.73%) and 4.39% (216/4 919, 95%CI: 2.29%-6.50%) respectively in hemodialysis patients, 0.85% (44/5 200, 95%CI: 0.27%-1.42%) and 0.70% (36/5 150, 95%CI: 0.15%-1.24%) respectively in patients receiving invasive diagnosis and treatment and remained to be ≤0.25% in volunteer blood donors, people receiving physical examination and clients visiting family planning outpatient clinics. Results for the comparison of the anti-HCV positive rates in the 5 populations indicated that the differences were significant (F=23.091, P<0.001 in 2016 and F=20.181, P<0.001 in 2017). Conclusions: Data from the sentinel surveillance of HCV infection on prevalence in China showed that the anti-HCV positive rates varied in the 5 populations during 2016-2017. The anti-HCV positive rate appeared the highest in the hemodialysis patients, followed by that in the patients receiving invasive diagnosis and treatment, and the prevalence of HCV infection in other 3 populations were at low levels.
